{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:23:41Z","timestamp":1780892621879,"version":"3.54.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008397","name":"Velux Fonden","doi-asserted-by":"publisher","award":["VELUX25723"],"award-info":[{"award-number":["VELUX25723"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","award":["20\/14779"],"award-info":[{"award-number":["20\/14779"]}],"id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","award":["22\/26201"],"award-info":[{"award-number":["22\/26201"]}],"id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013814","name":"Klinisk Institut, Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","award":["10-001584"],"award-info":[{"award-number":["10-001584"]}],"id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008214","name":"K\u00f8bmand Sven Hansen og Hustru Ina Hansens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008214","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Biomedical Laboratory Scientist Education and Research Fund"},{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","award":["R128-A5232"],"award-info":[{"award-number":["R128-A5232"]}],"id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dansk Knogle Selskab"},{"DOI":"10.13039\/501100021851","name":"William Demant Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00198-025-07612-z","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:07:50Z","timestamp":1757416070000},"page":"2411-2435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans\u2014a histomorphometry centered scoping review"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7552-5974","authenticated-orcid":false,"given":"Lisbeth Koch","family":"Thomsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-1232","authenticated-orcid":false,"given":"Pernille","family":"van Dijk Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2624-5677","authenticated-orcid":false,"given":"Christina M\u00f8ller","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6981-7276","authenticated-orcid":false,"given":"Thomas Levin","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"7612_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","volume":"40","author":"JE Compston","year":"2007","unstructured":"Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40:1447\u20131452. https:\/\/doi.org\/10.1016\/j.bone.2006.09.008","journal-title":"Bone"},{"key":"7612_CR2","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","volume":"40","author":"RL Jilka","year":"2007","unstructured":"Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434\u20131446. https:\/\/doi.org\/10.1016\/j.bone.2007.03.017","journal-title":"Bone"},{"key":"7612_CR3","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1210\/er.2004-0006","volume":"26","author":"AB Hodsman","year":"2005","unstructured":"Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Chui KY (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688\u2013703. https:\/\/doi.org\/10.1210\/er.2004-0006","journal-title":"Endocr Rev"},{"key":"7612_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1358\/dot.2004.40.11.872582","volume":"40","author":"EF Eriksen","year":"2004","unstructured":"Eriksen EF, Robins DA (2004) Teriparatide - a bone formation treatment for osteoporosis. Drugs of Today 40:935\u2013948. https:\/\/doi.org\/10.1358\/dot.2004.40.11.872582","journal-title":"Drugs of Today"},{"key":"7612_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1677\/joe.1.06057","volume":"187","author":"JT Potts","year":"2005","unstructured":"Potts JT (2005) Parathyroid hormone: past and present. J Endocrinol 187:311\u2013325. https:\/\/doi.org\/10.1677\/joe.1.06057","journal-title":"J Endocrinol"},{"key":"7612_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","volume":"47","author":"D Goltzman","year":"2018","unstructured":"Goltzman D (2018) Physiology of parathyroid hormone, endocrinol. Metab Clin North Am 47:743\u2013758. https:\/\/doi.org\/10.1016\/j.ecl.2018.07.003","journal-title":"Metab Clin North Am"},{"key":"7612_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00223-011-9564-3","volume":"90","author":"P Schwarz","year":"2012","unstructured":"Schwarz P, Jorgensen NR, Mosekilde L, Vestergaard P (2012) Effects of increasing age, dosage, and duration of PTH treatment on BMD increase - a meta-analysis. Calcif Tissue Int 90:165\u2013173. https:\/\/doi.org\/10.1007\/s00223-011-9564-3","journal-title":"Calcif Tissue Int"},{"key":"7612_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1210\/edrv-14-6-690","volume":"14","author":"DW Dempster","year":"1993","unstructured":"Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone*. Endocr Rev 14:690\u2013709. https:\/\/doi.org\/10.1210\/edrv-14-6-690","journal-title":"Endocr Rev"},{"key":"7612_CR9","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1073\/pnas.67.4.1862","volume":"67","author":"HB Brewer","year":"1970","unstructured":"Brewer HB, Ronan R (1970) Bovine parathyroid hormone: amino acid sequence. Proc Natl Acad Sci U S A 67:1862\u20131869. https:\/\/doi.org\/10.1073\/pnas.67.4.1862","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7612_CR10","unstructured":"Niall HD, Keutmann H, Sauer R, Hogan M, Dawson B, Aurbach G, Potts J (1970) The amino acid sequence of bovine parathyroid hormone I, Hoppe. Seylers. Z. Physiol. Chem. 351 (1970) 1586\u20141588. http:\/\/europepmc.org\/abstract\/MED\/5531031."},{"issue":"12","key":"7612_CR11","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1016\/S0021-9258(18)69644-9","volume":"234","author":"GD Aurbach","year":"1959","unstructured":"Aurbach GD (1959) Isolation of parathyroid hormone after extraction with phenol. J Biol Chem 234(12):3179\u201381. https:\/\/doi.org\/10.1016\/S0021-9258(18)69644-9","journal-title":"J Biol Chem"},{"key":"7612_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s0021-9258(18)85007-4","volume":"63","author":"JB Collip","year":"1925","unstructured":"Collip JB (1925) The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regulates the level of blood calcium. J Biol Chem 63:395\u2013438. https:\/\/doi.org\/10.1016\/s0021-9258(18)85007-4","journal-title":"J Biol Chem"},{"key":"7612_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1210\/jcem-56-3-572","volume":"56","author":"EM Brown","year":"1983","unstructured":"Brown EM (1983) Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572\u2013581. https:\/\/doi.org\/10.1210\/jcem-56-3-572","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR14","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nrm1154","volume":"4","author":"AM Hofer","year":"2003","unstructured":"Hofer AM, Brown EM (2003) Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4:530\u2013538. https:\/\/doi.org\/10.1038\/nrm1154","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7612_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/sj.ejcn.1601463","volume":"56","author":"AD Conigrave","year":"2002","unstructured":"Conigrave AD, Franks AH, Brown EM, Quinn SJ (2002) L-Amino acid sensing by the calcium-sensing receptor: a general mechanism for coupling protein and calcium metabolism? Eur J Clin Nutr 56:1072\u20131080. https:\/\/doi.org\/10.1038\/sj.ejcn.1601463","journal-title":"Eur J Clin Nutr"},{"key":"7612_CR16","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/jbmr.5650101213","volume":"10","author":"B Fermor","year":"1995","unstructured":"Fermor B, Skerry TM (1995) PTH\/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res 10:1935\u20131943. https:\/\/doi.org\/10.1002\/jbmr.5650101213","journal-title":"J Bone Miner Res"},{"key":"7612_CR17","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1210\/en.2003-1185","volume":"145","author":"WB Sneddon","year":"2004","unstructured":"Sneddon WB, Magyar CE, Willick GE, Syme CA, Galbiati F, Bisello A, Friedman PA (2004) Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. Endocrinology 145:2815\u20132823. https:\/\/doi.org\/10.1210\/en.2003-1185","journal-title":"Endocrinology"},{"key":"7612_CR18","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1073\/pnas.69.7.1673","volume":"69","author":"M Garabedian","year":"1972","unstructured":"Garabedian M, Holick MF, Deluca HF, Boyle IT (1972) Control of 25-hydroxycholecalciferol metabolism by parathyroid glands. Proc Natl Acad Sci U S A 69:1673\u20131676. https:\/\/doi.org\/10.1073\/pnas.69.7.1673","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7612_CR19","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1152\/ajpendo.1984.246.2.E168","volume":"246","author":"Y Tanaka","year":"1984","unstructured":"Tanaka Y, DeLuca HF (1984) Rat renal 25-hydroxyvitamin D3 l- and 25-hydroxylases: their in vivo regulation. Am J Physiol - Endocrinol Metab 246:E123\u2013E207","journal-title":"Am J Physiol - Endocrinol Metab"},{"key":"7612_CR20","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1073\/pnas.95.4.1387","volume":"95","author":"HL Brenza","year":"1998","unstructured":"Brenza HL, Kimmel-Jehan C, Jehan F, Shinki T, Wakino S, Anazawa H, Suda T, DeLuca HF (1998) Parathyroid hormone activation of the 25-hydroxyvitamin D3\u20131\u03b1-hydroxylase gene promoter. Proc Natl Acad Sci U S A 95:1387\u20131391. https:\/\/doi.org\/10.1073\/pnas.95.4.1387","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7612_CR21","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cellsig.2009.02.012","volume":"21","author":"NS Datta","year":"2009","unstructured":"Datta NS, Abou-Samra AB (2009) PTH and PTHrP signaling in osteoblasts. Cell Signal 21:1245\u20131254. https:\/\/doi.org\/10.1016\/j.cellsig.2009.02.012","journal-title":"Cell Signal"},{"key":"7612_CR22","doi-asserted-by":"publisher","first-page":"F665","DOI":"10.1152\/ajprenal.1999.277.5.f665","volume":"277","author":"M Mannstadt","year":"1999","unstructured":"Mannstadt M, J\u00fcppner H, Gardella TJ (1999) Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol - Ren Physiol 277:F665\u2013F675. https:\/\/doi.org\/10.1152\/ajprenal.1999.277.5.f665","journal-title":"Am J Physiol - Ren Physiol"},{"key":"7612_CR23","doi-asserted-by":"publisher","unstructured":"Silva BC, Bilezikian JP (2015) Anabolic and catabolic pathways of parathyroid hormone on the skeleton. Parathyroids Basic Clin. Concepts (Third Ed.) pp 233\u2013244. https:\/\/doi.org\/10.1016\/B978-0-12-397166-1.00015-1","DOI":"10.1016\/B978-0-12-397166-1.00015-1"},{"key":"7612_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/endo-123-1-187","volume":"123","author":"MF Rouleau","year":"1988","unstructured":"Rouleau MF, Mitchell J, Goltzman D (1988) In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast*. Endocrinology 123:187\u2013191. https:\/\/doi.org\/10.1210\/endo-123-1-187","journal-title":"Endocrinology"},{"key":"7612_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/206489a0","volume":"206","author":"R Hattner","year":"1965","unstructured":"Hattner R, Epker BN, Frost HM (1965) Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206:489\u2013490. https:\/\/doi.org\/10.1038\/206489a0","journal-title":"Nature"},{"key":"7612_CR26","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1007\/BF01673408","volume":"53","author":"AM Parfitt","year":"1993","unstructured":"Parfitt AM (1993) Bone age, mineral density, and fatigue damage. Calcif Tissue Int 53:S82\u2013S86. https:\/\/doi.org\/10.1007\/BF01673408","journal-title":"Calcif Tissue Int"},{"key":"7612_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ajpath.2013.03.006","volume":"183","author":"TL Andersen","year":"2013","unstructured":"Andersen TL, Abdelgawad ME, Kristensen HB, Hauge EM, Rolighed L, Bollerslev J, Kj\u00e6rsgaard-Andersen P, Delaisse JM (2013) Understanding coupling between bone resorption and formation: are reversal cells the missing link? Am J Pathol 183:235\u2013246. https:\/\/doi.org\/10.1016\/j.ajpath.2013.03.006","journal-title":"Am J Pathol"},{"issue":"7","key":"7612_CR28","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/jbmr.3091","volume":"32","author":"NE Lassen","year":"2017","unstructured":"Lassen NE, Andersen TL, Pl\u00f8en GG, S\u00f8e K, Hauge EM, Harving S, Eschen GE, Delaisse JM (2017) Coupling of bone resorption and formation in real time: new knowledge gained from human Haversian BMUs. J Bone Mineral Res 32(7):1395\u2013405. https:\/\/doi.org\/10.1002\/jbmr.3091","journal-title":"J Bone Mineral Res"},{"key":"7612_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00418-016-1414-y","volume":"145","author":"ME Abdelgawad","year":"2016","unstructured":"Abdelgawad ME, Delaisse JM, Hinge M, Jensen PR, Alnaimi RW, Rolighed L, Engelholm LH, Marcussen N, Andersen TL (2016) Early reversal cells in adult human bone remodeling: osteoblastic nature, catabolic functions and interactions with osteoclasts. Histochem Cell Biol 145:603\u2013615. https:\/\/doi.org\/10.1007\/s00418-016-1414-y","journal-title":"Histochem Cell Biol"},{"key":"7612_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2022.896841","volume":"9","author":"XG Borggaard","year":"2022","unstructured":"Borggaard XG, Nielsen MH, Delaisse JM, Andreasen CM, Andersen TL (2022) Spatial organization of osteoclastic coupling factors and their receptors at human bone remodeling sites. Front Mol Biosci 9:1\u201312. https:\/\/doi.org\/10.3389\/fmolb.2022.896841","journal-title":"Front Mol Biosci"},{"key":"7612_CR31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jbmr.4815","volume":"38","author":"TL Andersen","year":"2023","unstructured":"Andersen TL, Jensen PR, Sikjaer TT, Rejnmark L, Ejersted C, Delaisse JM (2023) A critical role of the bone marrow envelope in human bone remodeling. J Bone Miner Res 38:918\u2013928. https:\/\/doi.org\/10.1002\/jbmr.4815","journal-title":"J Bone Miner Res"},{"key":"7612_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/path.1711450403","volume":"145","author":"TJ Chambers","year":"1985","unstructured":"Chambers TJ, Fuller K, McSheehy PMJ, Pringle JAS (1985) The effects of calcium regulating hormones on bone resorption by isolated human osteoclastoma cells. J Pathol 145:297\u2013305. https:\/\/doi.org\/10.1002\/path.1711450403","journal-title":"J Pathol"},{"issue":"2","key":"7612_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1210\/endo-118-2-824","volume":"118","author":"PM McSheehy","year":"1986","unstructured":"McSheehy PM, Chambers TJ (1986) Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology. 118(2):824\u20138. https:\/\/doi.org\/10.1210\/endo-118-2-824","journal-title":"Endocrinology."},{"key":"7612_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0378-5122(96)01015-8","volume":"23","author":"HK V\u00e4\u00e4n\u00e4nen","year":"1996","unstructured":"V\u00e4\u00e4n\u00e4nen HK, H\u00e4rk\u00f6nen PL (1996) Estrogen and bone metabolism. Maturitas 23:65\u201369","journal-title":"Maturitas"},{"key":"7612_CR35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","volume":"13","author":"BL Riggs","year":"1998","unstructured":"Riggs BL, Khosla S, Melton LJ (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763\u2013773. https:\/\/doi.org\/10.1359\/jbmr.1998.13.5.763","journal-title":"J Bone Miner Res"},{"key":"7612_CR36","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/jbmr.262","volume":"26","author":"S Khosla","year":"2011","unstructured":"Khosla S, Melton LJ, Riggs BL (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26:441\u2013451. https:\/\/doi.org\/10.1002\/jbmr.262","journal-title":"J Bone Miner Res"},{"key":"7612_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/jbmr.3354","volume":"33","author":"CM Andreasen","year":"2018","unstructured":"Andreasen CM, Delaisse JM, van der Eerden BCJ, van Leeuwen JPTM, Ding M, Andersen TL (2018) Understanding age-induced cortical porosity in women: the accumulation and coalescence of eroded cavities upon existing intracortical canals is the main contributor. J Bone Miner Res 33:606\u2013620. https:\/\/doi.org\/10.1002\/jbmr.3354","journal-title":"J Bone Miner Res"},{"issue":"130","key":"7612_CR38","doi-asserted-by":"publisher","first-page":"115127","DOI":"10.1016\/j.bone.2019.115127","volume":"1","author":"CM Andreasen","year":"2020","unstructured":"Andreasen CM, Bakalova LP, Br\u00fcel A, Hauge EM, Kiil BJ, Delaisse JM, Kersh ME, Thomsen JS, Andersen TL (2020) The generation of enlarged eroded pores upon existing intracortical canals is a major contributor to endocortical trabecularization. Bone. 1(130):115127. https:\/\/doi.org\/10.1016\/j.bone.2019.115127","journal-title":"Bone."},{"key":"7612_CR39","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/JBMR.050304","volume":"20","author":"O Johnell","year":"2005","unstructured":"Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O\u2019Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185\u20131194. https:\/\/doi.org\/10.1359\/JBMR.050304","journal-title":"J Bone Miner Res"},{"key":"7612_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377:1276\u20131287. https:\/\/doi.org\/10.1016\/S0140-6736(10)62349-5","journal-title":"Lancet"},{"key":"7612_CR41","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018. https:\/\/doi.org\/10.1016\/S0140-6736(06)68891-0","journal-title":"Lancet"},{"key":"7612_CR42","doi-asserted-by":"publisher","unstructured":"Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Reijnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM (2017) Hypoparathyroidism, Nat. Rev. Dis. Prim. 3. https:\/\/doi.org\/10.1038\/nrdp.2017.55.","DOI":"10.1038\/nrdp.2017.55"},{"key":"7612_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1056\/NEJMcp0803050","volume":"359","author":"D Shoback","year":"2008","unstructured":"Shoback D (2008) Hypoparathyroidism. N Engl J Med 359:391\u2013403. https:\/\/doi.org\/10.1056\/NEJMcp0803050","journal-title":"N Engl J Med"},{"key":"7612_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/8756-3282(95)00443-2","volume":"18","author":"BL Langdahl","year":"1996","unstructured":"Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P (1996) Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 18:103\u2013108. https:\/\/doi.org\/10.1016\/8756-3282(95)00443-2","journal-title":"Bone"},{"key":"7612_CR45","doi-asserted-by":"publisher","unstructured":"Sikjaer T, Hypoparathyroidism and the skeleton, in: N.E. Cusano (Ed.), Hypoparathyroidism A Clin. Caseb., Springer Nature Switzerland AG, 2019: pp. 133\u2013141. https:\/\/doi.org\/10.1007\/978-3-030-29433-5_14.","DOI":"10.1007\/978-3-030-29433-5_14"},{"key":"7612_CR46","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1210\/jc.2002-021388","volume":"88","author":"FKW Chan","year":"2003","unstructured":"Chan FKW, Tiu S-C, Choi K-L, Choi C-H, Kong APS, Shek C-C (2003) Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 88:3155\u20133159. https:\/\/doi.org\/10.1210\/jc.2002-021388","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR47","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1210\/jcem.76.6.8501170","volume":"76","author":"S Abugassa","year":"1993","unstructured":"Abugassa S, Nordenstr\u00f6m J, Eriksson S, Sj\u00f6d\u00e9n G (1993) Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 76:1617\u20131621. https:\/\/doi.org\/10.1210\/jcem.76.6.8501170","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR48","unstructured":"Hussein S, Afifi H, AbuAlrob H, Almoulia A, Azharruddin A, Bole D, Braga M, Cheng A, Cheung R, Young JEM, Khan S, Khan T, Malhem J, Malik H, Mehmood S, Millar A, Morgante E, Naveed F, Niazi H, Pauls T, Prebtani A, Punthakee Z, Shaban J, Shah R, Shrayyef M, Tagra C, Teschke S, Treki I, Tauqir R, van Uum S, Ovize M (2023) Skeletal effects of hypoparathyroidism (HypoPT); data from the Canadian National Hypoparathyroidism Registry (CNHR), J. Bone Miner. Res. SUN-592. https:\/\/www.asbmr.org\/meetings\/annualmeeting\/AbstractDetail?aid=32210cfd-359e-471c-92bb-284690a482b8."},{"key":"7612_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-025-07410-7","volume":"16","author":"AA Khan","year":"2025","unstructured":"Khan AA, AbuAlrob H, Ali DS, Al Kassem Z, Almoulia A, Afifi H, Braga M, Cheng A, Malhem J, Millar A, Morgante E (2025) Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian National Hypoparathyroidism Registry (CNHR). Osteopor Int 16:1\u20132. https:\/\/doi.org\/10.1007\/s00198-025-07410-7","journal-title":"Osteopor Int"},{"key":"7612_CR50","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jbmr.2501","volume":"30","author":"L Underbjerg","year":"2015","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738\u20131744. https:\/\/doi.org\/10.1002\/jbmr.2501","journal-title":"J Bone Miner Res"},{"key":"7612_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6823-13-1","volume":"13","author":"ML Mendon\u00e7a","year":"2013","unstructured":"Mendon\u00e7a ML, Pereira FA, Nogueira-Barbosa MH, Monsignore LM, Teixeira SR, Watanabe PCA, Maciel LMZ, de Paula FJA (2013) Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr Disord 13:1\u20138. https:\/\/doi.org\/10.1186\/1472-6823-13-1","journal-title":"BMC Endocr Disord"},{"key":"7612_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1210\/jc.2016-3292","volume":"102","author":"H Chawla","year":"2017","unstructured":"Chawla H, Saha S, Kandasamy D, Sharma R, Sreenivas V, Goswami R (2017) Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long-term follow-up. J Clin Endocrinol Metab 102:251\u2013258. https:\/\/doi.org\/10.1210\/jc.2016-3292","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR53","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/jbmr.2273","volume":"29","author":"L Underbjerg","year":"2014","unstructured":"Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2014) Postsurgical hypoparathyroidism-risk of fractures, Psychiatric Diseases, Cancer, Cataract, and Infections. J Bone Miner Res 29:2504\u20132510. https:\/\/doi.org\/10.1002\/jbmr.2273","journal-title":"J Bone Miner Res"},{"key":"7612_CR54","doi-asserted-by":"crossref","unstructured":"Suva LJ, Winslow GA, Wettenhall RH, Hammonds RG, Moseley JM, Diefenbach-Jagger H, Rodda CP, Kemp BE, Rodriguez H, Chen EY, Hudson PJ. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science. 1987 Aug 21;237(4817):893-6. http:\/\/www.jstor.org.proxy1-bib.sdu.dk:2048\/stable\/1699896.","DOI":"10.1126\/science.3616618"},{"key":"7612_CR55","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2741\/3656","volume":"15","author":"M Wu","year":"2010","unstructured":"Wu M, Deng L, Zhu G, Li Y-P (2010) G Protein and its signaling pathway in bone development and disease. Front Biosci 15:957\u2013985","journal-title":"Front Biosci"},{"key":"7612_CR56","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1172\/JCI6610","volume":"104","author":"RL Jilka","year":"1999","unstructured":"Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC (1999) Increased bone formation byprevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439\u2013446. https:\/\/doi.org\/10.1172\/JCI6610","journal-title":"J Clin Invest"},{"key":"7612_CR57","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1359\/jbmr.070104","volume":"22","author":"R Lindsay","year":"2007","unstructured":"Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB (2007) Effects of a one-month treatment with PTH(1\u201334) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res 22:495\u2013502. https:\/\/doi.org\/10.1359\/jbmr.070104","journal-title":"J Bone Miner Res"},{"key":"7612_CR58","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","volume":"136","author":"H Dobnig","year":"1995","unstructured":"Dobnig H, Turner RT (1995) Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136:3632\u20133638. https:\/\/doi.org\/10.1210\/endo.136.8.7628403","journal-title":"Endocrinology"},{"key":"7612_CR59","unstructured":"FDA, Drug Approval Package: Forteo, (2004). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-318_Forteo.cfm (accessed November 22, 2024)."},{"key":"7612_CR60","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/00006254-200110000-00018","volume":"56","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. Obstet Gynecol Surv 56:623\u2013624. https:\/\/doi.org\/10.1097\/00006254-200110000-00018","journal-title":"Obstet Gynecol Surv"},{"key":"7612_CR61","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0169-6009(90)90080-Y","volume":"9","author":"AB Hodsman","year":"1990","unstructured":"Hodsman AB, Fraher LJ (1990) Biochemical responses to sequential human parathyroid hormone (1\u201338) and calcitonin in osteoporotic patients. Bone Miner 9:137\u2013152. https:\/\/doi.org\/10.1016\/0169-6009(90)90080-Y","journal-title":"Bone Miner"},{"key":"7612_CR62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0169-6009(91)90103-7","volume":"14","author":"AB Hodsman","year":"1991","unstructured":"Hodsman AB, Steer BM, Fraher LJ, Drost DJ (1991) Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1\u201338) and salmon calcitonin in osteoporotic patients. Bone Miner 14:67\u201383. https:\/\/doi.org\/10.1016\/0169-6009(91)90103-7","journal-title":"Bone Miner"},{"issue":"10","key":"7612_CR63","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1055\/s-2007-1014852","volume":"16","author":"RD Hesch","year":"1984","unstructured":"Hesch RD, Heck J, Auf\u2019mKolk B, Schettler T, Atkinson MJ (1984) First clinical observations with hPTH (1\u201338), a more potent human parathyroid hormone peptide. Hormone Metab Res 16(10):559\u201360. https:\/\/doi.org\/10.1055\/s-2007-1014852","journal-title":"Hormone Metab Res"},{"key":"7612_CR64","unstructured":"FDA, Drug Approval Package Natpara, (2015). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125511Orig1s000TOC.cfm (accessed November 22, 2024)."},{"key":"7612_CR65","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/157488611795684631","volume":"6","author":"T Sikjaer","year":"2012","unstructured":"Sikjaer T, Rejnmark L, Mosekilde L (2012) PTH treatment in hypoparathyroidism. Curr Drug Saf 6:89\u201399. https:\/\/doi.org\/10.2174\/157488611795684631","journal-title":"Curr Drug Saf"},{"key":"7612_CR66","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/jbmr.470","volume":"26","author":"T Sikjaer","year":"2011","unstructured":"Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L (2011) The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26:2358\u20132370. https:\/\/doi.org\/10.1002\/jbmr.470","journal-title":"J Bone Miner Res"},{"key":"7612_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1530\/eje.0.1460215","volume":"146","author":"W Arlt","year":"2002","unstructured":"Arlt W, Fremerey C, Callies F, Reincke M, Schneider P, Timmermann W, Allolio B (2002) Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol 146:215\u2013222. https:\/\/doi.org\/10.1530\/eje.0.1460215","journal-title":"Eur J Endocrinol"},{"key":"7612_CR68","unstructured":"FDA, FDA approves new drug for hypoparathyroidism, a rare disorder, (2024). https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-drug-hypoparathyroidism-rare-disorder (accessed November 22, 2024)."},{"issue":"4","key":"7612_CR69","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1210\/clinem\/dgae693","volume":"110","author":"BL Clarke","year":"2024","unstructured":"Clarke BL, Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, Palermo A, Abbott LG, Hofbauer LC, Kohlmeier L (2024) Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial. J Clinic Endocrinol Metabol 110(4):951\u201360. https:\/\/doi.org\/10.1210\/clinem\/dgae693","journal-title":"J Clinic Endocrinol Metabol"},{"key":"7612_CR70","doi-asserted-by":"publisher","unstructured":"Hartley IR, Gafni RI, Roszko KL, Li X, Ferguson EA, Moore CA, Pozo KA, Ampuero KT, Sridhar AV, Mathew AS, Roberts M. 12520 Preliminary Findings From An Ongoing Open-label Phase 2 Study Demonstrate That The Calcilytic Encaleret Can Improve The Relationship Between Blood And Urinary Calcium In Individuals With Post-surgical Hypoparathyroidism. Journal of the Endocrine Society. 2024 Oct;8(Supplement_1):bvae163-476. https:\/\/doi.org\/10.1210\/jendso\/bvae163.476.","DOI":"10.1210\/jendso\/bvae163.476"},{"key":"7612_CR71","unstructured":"FDA, Drug Trial snapshot TYMLOS, (2017). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-tymlos (accessed November 22, 2024)."},{"key":"7612_CR72","unstructured":"European Medicines Agency, Eladynos Overview, (2024). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eladynos (accessed November 22, 2024)."},{"key":"7612_CR73","unstructured":"European Medicines Agency, Refusal of marketing authorisation for Eladynos, (2018). https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-and-answers-refusal-marketing-authorisation-eladynos-abaloparatide_en.pdf (accessed November 22, 2024)."},{"key":"7612_CR74","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1177\/1060028017748649","volume":"52","author":"EG Boyce","year":"2018","unstructured":"Boyce EG, Mai Y, Pham C (2018) Abaloparatide: review of a next-generation parathyroid hormone agonist. Ann Pharmacother 52:462\u2013472. https:\/\/doi.org\/10.1177\/1060028017748649","journal-title":"Ann Pharmacother"},{"key":"7612_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344. https:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"},{"key":"7612_CR76","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1210\/jc.2015-2957","volume":"100","author":"P Chavassieux","year":"2015","unstructured":"Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R (2015) Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women? J Clin Endocrinol Metab 100:4662\u20134668. https:\/\/doi.org\/10.1210\/jc.2015-2957","journal-title":"J Clin Endocrinol Metab"},{"issue":"141","key":"7612_CR77","doi-asserted-by":"publisher","first-page":"115628","DOI":"10.1016\/j.bone.2020.115628","volume":"1","author":"JM Delaisse","year":"2020","unstructured":"Delaisse JM, Andersen TL, Kristensen HB, Jensen PR, Andreasen CM, S\u00f8e K (2020) Re-thinking the bone remodeling cycle mechanism and the origin of bone loss. Bone 1(141):115628. https:\/\/doi.org\/10.1016\/j.bone.2020.115628","journal-title":"Bone"},{"key":"7612_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9\u201317. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.9","journal-title":"J Bone Miner Res"},{"key":"7612_CR79","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1210\/jc.2015-3698","volume":"101","author":"F Cosman","year":"2016","unstructured":"Cosman F, Dempster DW, Nieves JW, Zhou H, Zion M, Roimisher C, Houle Y, Lindsay R, Bostrom M (2016) Effect of teriparatide on bone formation in the human femoral neck. J Clin Endocrinol Metab 101:1498\u20131505. https:\/\/doi.org\/10.1210\/jc.2015-3698","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41413-024-00362-4","volume":"12","author":"BM El-Masri","year":"2024","unstructured":"El-Masri BM, Andreasen CM, Laursen KS, Kofod VB, Dahl XG, Nielsen MH, Thomsen JS, Br\u00fcel A, S\u00f8rensen MS, Hansen LJ, Kim AS, Taylor VE, Massarotti C, McDonald MM, You X, Charles JF, Delaisse J-M, Andersen TL (2024) Mapping RANKL- and OPG-expressing cells in bone tissue: the bone surface cells as activators of osteoclastogenesis and promoters of the denosumab rebound effect. Bone Res 12:62. https:\/\/doi.org\/10.1038\/s41413-024-00362-4","journal-title":"Bone Res"},{"key":"7612_CR81","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/jbmr.1506","volume":"27","author":"EC Walker","year":"2012","unstructured":"Walker EC, Poulton IJ, McGregor NE, Ho PWM, Allan EH, Quach JM, Martin TJ, Sims NA (2012) Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. J Bone Miner Res 27:902\u2013912. https:\/\/doi.org\/10.1002\/jbmr.1506","journal-title":"J Bone Miner Res"},{"key":"7612_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1359\/JBMR.0301226","volume":"19","author":"JC Huang","year":"2004","unstructured":"Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA (2004) PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 19:235\u2013244. https:\/\/doi.org\/10.1359\/JBMR.0301226","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7612_CR83","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR, Parfitt AM (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28(1):2\u201317. https:\/\/doi.org\/10.1002\/jbmr.1805","journal-title":"J Bone Miner Res"},{"key":"7612_CR84","first-page":"536","volume":"29","author":"K Keller","year":"2011","unstructured":"Keller K, Stengaard-Pedersen K, Dagnaes-Hansen F, Nyengaard JR, Sakaguchi S, Hauge EM (2011) Histological changes in chronic autoimmune SKG-arthritis evaluated by quantitative three-dimensional stereological estimators. Clin Exp Rheumatol 29:536\u2013543","journal-title":"Clin Exp Rheumatol"},{"key":"7612_CR85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2818.1986.tb02764.x","volume":"143","author":"HJG Gundersen","year":"1986","unstructured":"Gundersen HJG (1986) Stereology of arbitrary particles. J Microsc 143:3\u201345. https:\/\/doi.org\/10.1111\/j.1365-2818.1986.tb02764.x","journal-title":"J Microsc"},{"key":"7612_CR86","doi-asserted-by":"publisher","unstructured":"T.L. Andersen, J.M. Delaisse, J.S. Thomsen, C.M. Andreasen, Significance of reversal-resorption phase in bone loss, in: H.E. Takahashi, D.B. Burr, N. Yamamoto (Eds.), Osteoporotic Fract. Syst. Skelet. Disord. Mech. Assessment, Treat., Springer Nature Singapore, 2021: pp. 101\u2013110. https:\/\/doi.org\/10.1007\/978-981-16-5613-2_7.","DOI":"10.1007\/978-981-16-5613-2_7"},{"key":"7612_CR87","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1172\/JCI200317215","volume":"111","author":"G Eghbali-Fatourechi","year":"2003","unstructured":"Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111:1221\u20131230. https:\/\/doi.org\/10.1172\/JCI200317215","journal-title":"J Clin Invest"},{"key":"7612_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-06614-0","volume":"7","author":"C Streicher","year":"2017","unstructured":"Streicher C, Heyny A, Andrukhova O, Haigl B, Slavic S, Sch\u00fcler C, Kollmann K, Kantner I, Sexl V, Kleiter M, Hofbauer LC, Kostenuik PJ, Erben RG (2017) Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci Rep 7:1\u201314. https:\/\/doi.org\/10.1038\/s41598-017-06614-0","journal-title":"Sci Rep"},{"key":"7612_CR89","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0749-0690(02)00074-5","volume":"19","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Bilezikian JP (2003) The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 19:415\u2013432. https:\/\/doi.org\/10.1016\/S0749-0690(02)00074-5","journal-title":"Clin Geriatr Med"},{"key":"7612_CR90","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3171\/2021.5.SPINE202003","volume":"36","author":"K Sawakami","year":"2022","unstructured":"Sawakami K, Watanabe K, Hasegawa K, Yamamoto N, Shimakura T, Ohashi M, Shoji H, Mizouchi T, Tanaka Y, Segawa H, Ishikawa S, Hirano T, Kawashima H, Endo N, Takahashi E (2022) Hideaki, Neoadjuvant teriparatide therapy targeting the osteoporotic spine: influence of administration period from the perspective of bone histomorphometry. J Neurosurg Spine 36:429\u2013439. https:\/\/doi.org\/10.3171\/2021.5.SPINE202003","journal-title":"J Neurosurg Spine"},{"key":"7612_CR91","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1359\/JBMR.051109","volume":"21","author":"R Lindsay","year":"2006","unstructured":"Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JAD, Nieves JW, Dempster DW (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21:366\u2013373. https:\/\/doi.org\/10.1359\/JBMR.051109","journal-title":"J Bone Miner Res"},{"issue":"7","key":"7612_CR92","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1359\/JBMR.050309","volume":"20","author":"M Arlot","year":"2005","unstructured":"Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, Martin JS, Eriksen EF (2005) Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Mine Res 20(7):1244\u201353. https:\/\/doi.org\/10.1359\/JBMR.050309","journal-title":"J Bone Mine Res"},{"key":"7612_CR93","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bone.2008.09.019","volume":"44","author":"RR Recker","year":"2009","unstructured":"Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J (2009) Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1\u201384. Bone 44:113\u2013119. https:\/\/doi.org\/10.1016\/j.bone.2008.09.019","journal-title":"Bone"},{"key":"7612_CR94","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","volume":"14","author":"AB Hodsman","year":"1993","unstructured":"Hodsman AB, Steer BM (1993) Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. Bone 14:523\u2013527. https:\/\/doi.org\/10.1016\/8756-3282(93)90190-L","journal-title":"Bone"},{"key":"7612_CR95","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","volume":"27","author":"AB Hodsman","year":"2000","unstructured":"Hodsman AB, Kisiel M, Adachi JD, Fraher LJ, Watson PH (2000) Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis. Bone 27:311\u2013318. https:\/\/doi.org\/10.1016\/S8756-3282(00)00316-1","journal-title":"Bone"},{"issue":"7968","key":"7612_CR96","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/s0140-6736(76)92216-9","volume":"307","author":"J Reeve","year":"1976","unstructured":"Reeve J, Hesp R, Williams D, Hulme P, Klenerman L, Zanelli J, Darby AJ, Tregear GW, Parsons JA (1976) Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis. The Lancet. 307(7968):1035\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(76)92216-9","journal-title":"The Lancet."},{"key":"7612_CR97","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","volume":"280","author":"J Reeve","year":"1980","unstructured":"Reeve J, Klenerman L, Meunier PJ, Edouard C, Courpron P, Parsons JA, Bernat M, Renier JC, Bijvoet OLM, Vismans FJFE, Neer RM, Slovik D, Potts JT (1980) Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J 280:1340\u20131344. https:\/\/doi.org\/10.1136\/bmj.280.6228.1340","journal-title":"Br Med J"},{"key":"7612_CR98","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF01625448","volume":"1","author":"J Reeve","year":"1991","unstructured":"Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, Edouard C, Hesp R, Hulme P, Ashby JP, Zanelli JM, Meunier PJ (1991) hPTH 1\u201334 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses. Osteoporos Int 1:162\u2013170. https:\/\/doi.org\/10.1007\/BF01625448","journal-title":"Osteoporos Int"},{"key":"7612_CR99","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF (2003) Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932\u20131941. https:\/\/doi.org\/10.1359\/jbmr.2003.18.11.1932","journal-title":"J Bone Miner Res"},{"key":"7612_CR100","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","volume":"16","author":"DW Dempster","year":"2001","unstructured":"Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plaveti\u0107 K, M\u00fcller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846\u20131853. https:\/\/doi.org\/10.1359\/jbmr.2001.16.10.1846","journal-title":"J Bone Miner Res"},{"key":"7612_CR101","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00198-009-1168-7","volume":"21","author":"JJ Stepan","year":"2010","unstructured":"Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalsk\u00e1 D, Pavo I (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 21:2027\u20132036. https:\/\/doi.org\/10.1007\/s00198-009-1168-7","journal-title":"Osteoporos Int"},{"key":"7612_CR102","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","volume":"59","author":"YL Ma","year":"2014","unstructured":"Ma YL, Zeng QQ, Chiang AY, Burr D, Li J, Dobnig H, Fahrleitner-Pammer A, Michalsk\u00e1 D, Marin F, Pavo I, Stepan JJ (2014) Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. Bone 59:139\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2013.11.011","journal-title":"Bone"},{"key":"7612_CR103","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694\u20131700. https:\/\/doi.org\/10.1210\/jc.2013-4440","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR104","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1210\/jc.2003-1703","volume":"90","author":"H Dobnig","year":"2005","unstructured":"Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970\u20133977. https:\/\/doi.org\/10.1210\/jc.2003-1703","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR105","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1210\/jcem.85.9.6818","volume":"85","author":"ES Kurland","year":"2000","unstructured":"Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers*. J Clin Endocrinol Metab 85:3069\u20133076. https:\/\/doi.org\/10.1210\/jcem.85.9.6818","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"7612_CR106","doi-asserted-by":"publisher","first-page":"e10829","DOI":"10.1002\/jbm4.10829","volume":"7","author":"Christiansen P van Dijk","year":"2023","unstructured":"van Dijk Christiansen P, Sikj\u00e6r T, Andreasen CM, Thomsen JS, Br\u00fcel A, Hauge EM, Delaisse JM, Rejnmark L, Andersen TL (2023) Transitory activation and improved transition from erosion to formation within intracortical bone remodeling in hypoparathyroid patients treated with rhPTH (1\u201384). J Bone Mine Res Plus 7(12):e10829. https:\/\/doi.org\/10.1002\/jbm4.10829","journal-title":"J Bone Mine Res Plus"},{"key":"7612_CR107","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1359\/jbmr.080803","volume":"23","author":"MR Rubin","year":"2008","unstructured":"Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney J Jr, Silverberg SJ, Bilezikian JP (2008) Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23:2018\u20132024","journal-title":"J Bone Miner Res"},{"key":"7612_CR108","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/jbmr.3543","volume":"33","author":"MR Rubin","year":"2018","unstructured":"Rubin MR, Zhou H, Cusano NE, Majeed R, Omeragic B, Gomez M, Nickolas TL, Dempster DW, Bilezikian JP (2018) The effects of long-term administration of rhPTH(1\u201384) in hypoparathyroidism by bone histomorphometry. J Bone Miner Res 33:1931\u20131939. https:\/\/doi.org\/10.1002\/jbmr.3543","journal-title":"J Bone Miner Res"},{"key":"7612_CR109","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1002\/jbmr.452","volume":"26","author":"MR Rubin","year":"2011","unstructured":"Rubin MR, Dempster DW, Sliney J, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP (2011) PTH(1\u201384) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26:2727\u20132736. https:\/\/doi.org\/10.1002\/jbmr.452","journal-title":"J Bone Miner Res"},{"key":"7612_CR110","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3109\/00313028009060080","volume":"12","author":"CR Dunstan","year":"1980","unstructured":"Dunstan CR, Evans RA (1980) Quantitative bone histology: a new method. Pathology 12:255\u2013264. https:\/\/doi.org\/10.3109\/00313028009060080","journal-title":"Pathology"},{"key":"7612_CR111","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF02058664","volume":"3","author":"HM Frost","year":"1969","unstructured":"Frost HM (1969) Tetracycline-based histological analysis of bone remodeling. Calcif Tissue Res 3:211\u2013237. https:\/\/doi.org\/10.1007\/BF02058664","journal-title":"Calcif Tissue Res"},{"key":"7612_CR112","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/edrv-7-4-379","volume":"7","author":"EF Eriksen","year":"1986","unstructured":"Eriksen EF (1986) Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 7:379\u2013408. https:\/\/doi.org\/10.1210\/edrv-7-4-379","journal-title":"Endocr Rev"},{"key":"7612_CR113","unstructured":"Parfitt AM. The physiologic and clinical significance of bone histomorphometric data. Bone histomorphometry: techniques and interpretation.. 1983:143-223."},{"key":"7612_CR114","doi-asserted-by":"publisher","unstructured":"Jensen PR, Andersen TL, Chavassieux P, Roux JP, Delaisse JM. Bisphosphonates impair the onset of bone formation at remodeling sites. Bone. 2021 145:115850. https:\/\/doi.org\/10.1016\/j.bone.2021.115850.","DOI":"10.1016\/j.bone.2021.115850"},{"key":"7612_CR115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF02408616","volume":"30","author":"CS Tam","year":"1980","unstructured":"Tam CS, Anderson W (1980) Tetracycline labeling of bone in vivo. Calcif Tissue Int 30:121\u2013125. https:\/\/doi.org\/10.1007\/BF02408616","journal-title":"Calcif Tissue Int"},{"key":"7612_CR116","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1210\/jcem-45-1-114","volume":"45","author":"MK Drezner","year":"1977","unstructured":"Drezner MK, Neelon F, Jowsey J, Lebovitz HE (1977) Hypoparathyroidism: a possible cause of osteomalacia. J Clin Endocrinol Metab 45:114\u2013122. https:\/\/doi.org\/10.1210\/jcem-45-1-114","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"7612_CR117","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0221-8747(82)90024-8","volume":"4","author":"J Kragstrup","year":"1982","unstructured":"Kragstrup J, Gundersen HJ, Melsen F, Mosekilde L (1982) Estimation of the three-dimensional wall thickness of completed remodeling sites in iliac trabecular bone. Metabol Bone Dis Relat Res 4(2):113\u20139. https:\/\/doi.org\/10.1016\/0221-8747(82)90024-8","journal-title":"Metabol Bone Dis Relat Res"},{"issue":"5","key":"7612_CR118","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/jbmr.5650020510","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Simon LS, Villanueva AR, Krane SM (1987Oct 1) Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Mine Res 2(5):427\u201336. https:\/\/doi.org\/10.1002\/jbmr.5650020510","journal-title":"J Bone Mine Res"},{"key":"7612_CR119","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/jbmr.2822","volume":"31","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Cosman F, Zhou H, Nieves JW, Bostrom M, Lindsay R (2016) Effects of daily or cyclic teriparatide on bone formation in the iliac crest in women on no prior therapy and in women on alendronate. J Bone Miner Res 31:1518\u20131526. https:\/\/doi.org\/10.1002\/jbmr.2822","journal-title":"J Bone Miner Res"},{"key":"7612_CR120","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/jbmr.4243","volume":"36","author":"DW Dempster","year":"2021","unstructured":"Dempster DW, Zhou H, Rao SD, Recknor C, Miller PD, Leder BZ, Annett M, Ominsky MS, Mitlak BH (2021) Early effects of abaloparatide on bone formation and resorption indices in postmenopausal women with osteoporosis. J Bone Miner Res 36:644\u2013653. https:\/\/doi.org\/10.1002\/jbmr.4243","journal-title":"J Bone Miner Res"},{"key":"7612_CR121","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","volume":"17","author":"CL Gregson","year":"2022","unstructured":"Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17:58. https:\/\/doi.org\/10.1007\/s11657-022-01061-5","journal-title":"Arch Osteoporos"},{"issue":"2","key":"7612_CR122","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ecl.2021.03.009","volume":"50","author":"RM Arceo-Mendoza","year":"2021","unstructured":"Arceo-Mendoza RM, Camacho PM (2021) Postmenopausal osteoporosis: latest guidelines. Endocrinol Metabol Clinic 50(2):167\u201378. https:\/\/doi.org\/10.1016\/j.ecl.2021.03.009","journal-title":"Endocrinol Metabol Clinic"},{"key":"7612_CR123","first-page":"232","volume":"7","author":"WSS Jee","year":"2007","unstructured":"Jee WSS, Tian XY, Setterberg RB (2007) Cancellous bone minimodeling-based formation: a Frost, Takahashi legacy. J Musculoskelet Neuronal Interact 7:232\u2013239","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"7612_CR124","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, O\u2019Dea LSL, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G (2015) Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 100:697\u2013706. https:\/\/doi.org\/10.1210\/jc.2014-3718","journal-title":"J Clin Endocrinol Metab"},{"key":"7612_CR125","doi-asserted-by":"crossref","unstructured":"Progress M, Canalis E, Giustina A, Bilezikian JP (2007) for osteoporosis, Bone 905\u2013916.","DOI":"10.1056\/NEJMra067395"},{"key":"7612_CR126","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1002\/jbmr.1627","volume":"27","author":"RI Gafni","year":"2012","unstructured":"Gafni RI, Brahim JS, Andreopoulou P, Bhattacharyya N, Kelly MH, Brillante BA, Reynolds JC, Zhou H, Dempster DW, Collins MT (2012) Daily parathyroid hormone 1\u201334 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. J Bone Miner Res 27:1811\u20131820. https:\/\/doi.org\/10.1002\/jbmr.1627","journal-title":"J Bone Miner Res"},{"key":"7612_CR127","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl B, Ferrari S, Dempster DW (2016) Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis 8:225\u2013235. https:\/\/doi.org\/10.1177\/1759720X16670154","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"7612_CR128","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.3309","volume":"33","author":"DW Dempster","year":"2018","unstructured":"Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA (2018) Remodeling- and modeling-based bone formation with teriparatide versus denosumab: a longitudinal analysis from baseline to 3 months in the AVA study. J Bone Miner Res 33:298\u2013306. https:\/\/doi.org\/10.1002\/jbmr.3309","journal-title":"J Bone Miner Res"},{"key":"7612_CR129","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/jbmr.3350","volume":"33","author":"DW Dempster","year":"2018","unstructured":"Dempster DW, Zhou H, Ruff VA, Melby TE, Alam J, Taylor KA (2018) Longitudinal effects of teriparatide or zoledronic acid on bone modeling- and remodeling-based formation in the SHOTZ study. J Bone Miner Res 33:627\u2013633. https:\/\/doi.org\/10.1002\/jbmr.3350","journal-title":"J Bone Miner Res"},{"key":"7612_CR130","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1359\/jbmr.060314","volume":"21","author":"YL Ma","year":"2006","unstructured":"Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF (2006) Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855\u2013864. https:\/\/doi.org\/10.1359\/jbmr.060314","journal-title":"J Bone Miner Res"},{"key":"7612_CR131","doi-asserted-by":"publisher","unstructured":"Frost M, Rahbek ET, Ejersted C, H\u00f8ilund-Carlsen PF, Bygum A, Thomsen JS, Andreasen CM, Andersen TL, Frederiksen AL. Modeling-based bone formation transforms trabeculae to cortical bone in the sclerotic areas in Buschke-Ollendorff syndrome. A case study of two females with LEMD3 variants. Bone. 2020 Jun 1;135:115313. https:\/\/doi.org\/10.1016\/j.bone.2020.115313.","DOI":"10.1016\/j.bone.2020.115313"},{"issue":"160","key":"7612_CR132","doi-asserted-by":"publisher","first-page":"116399","DOI":"10.1016\/j.bone.2022.116399","volume":"1","author":"BA Lamarche","year":"2022","unstructured":"Lamarche BA, Thomsen JS, Andreasen CM, Lievers WB, Andersen TL (2022) 2D size of trabecular bone structure units (BSU) correlate more strongly with 3D architectural parameters than age in human vertebrae. Bone. 1(160):116399. https:\/\/doi.org\/10.1016\/j.bone.2022.116399","journal-title":"Bone."},{"key":"7612_CR133","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/(SICI)1097-0185(199609)246:1<39::AID-AR5>3.0.CO;2-A","volume":"246","author":"RG Erben","year":"1996","unstructured":"Erben RG (1996) Trabecular and endocortical bone surfaces in the rat: modeling or remodeling? Anat Rec 246:39\u201346. https:\/\/doi.org\/10.1002\/(SICI)1097-0185(199609)246:1\/3c39::AID-AR5\/3e3.0.CO;2-A","journal-title":"Anat Rec"},{"key":"7612_CR134","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/jbmr.1665","volume":"27","author":"SW Kim","year":"2012","unstructured":"Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, Shin CS, Baek WY, Kim JE, Kronenberg HM (2012) Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 27:2075\u20132084. https:\/\/doi.org\/10.1002\/jbmr.1665","journal-title":"J Bone Miner Res"},{"key":"7612_CR135","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S8756-3282(02)00947-X","volume":"32","author":"S Kobayashi","year":"2003","unstructured":"Kobayashi S, Takahashi HE, Ito A, Saito N, Nawata M, Horiuchi H, Ohta H, Iorio R, Yamamoto N, Takaoka K (2003) Trabecular minimodeling in human iliac bone. Bone 32:163\u2013169. https:\/\/doi.org\/10.1016\/S8756-3282(02)00947-X","journal-title":"Bone"},{"issue":"4","key":"7612_CR136","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/ar.1092260404","volume":"226","author":"HM Frost","year":"1990","unstructured":"Frost HM (1990) Skeletal structural adaptations to mechanical usage (SATMU): 3. The hyaline cartilage modeling problem. The anatomical record. 226(4):423\u201332. https:\/\/doi.org\/10.1002\/ar.1092260404","journal-title":"The anatomical record."},{"key":"7612_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2018.00088","volume":"9","author":"H Sano","year":"2018","unstructured":"Sano H, Kondo N, Shimakura T, Fujisawa J, Kijima Y, Kanai T, Poole KES, Yamamoto N, Takahashi HE, Endo N (2018) Evidence for ongoing modeling-based bone formation in human femoral head trabeculae via forming minimodeling structures: a study in patients with fractures and arthritis. Front Endocrinol (Lausanne) 9:1\u20138. https:\/\/doi.org\/10.3389\/fendo.2018.00088","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7612_CR138","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/jbmr.4898","volume":"38","author":"H Sano","year":"2023","unstructured":"Sano H, Whitmarsh T, Skingle L, Shimakura T, Yamamoto N, Compston JE, Takahashi HE, Poole KES (2023) Buds of new bone formation within the femoral head of hip fracture patients coincide with zones of low osteocyte sclerostin. J Bone Miner Res 38:1603\u20131611. https:\/\/doi.org\/10.1002\/jbmr.4898","journal-title":"J Bone Miner Res"},{"key":"7612_CR139","doi-asserted-by":"publisher","unstructured":"Takahashi HE, Yamamoto N, Sano H, Shimakura T. Bone Minimodeling, Modeling-Based Bone Formation in Trabecular, Endocortical and Periosteal Bone. InOsteoporotic Fracture and Systemic Skeletal Disorders: Mechanism, Assessment, and Treatment 2021 Dec 1 (pp. 67-87). Singapore: Springer Singapore. . https:\/\/doi.org\/10.1007\/978-981-16-5613-2.","DOI":"10.1007\/978-981-16-5613-2"},{"key":"7612_CR140","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jbmr.4006","volume":"35","author":"DW Dempster","year":"2020","unstructured":"Dempster DW, Chines A, Bostrom MP, Nieves JW, Zhou H, Chen L, Pannacciulli N, Wagman RB, Cosman F (2020) Modeling-based bone formation in the human femoral neck in subjects treated with denosumab. J Bone Miner Res 35:1282\u20131288. https:\/\/doi.org\/10.1002\/jbmr.4006","journal-title":"J Bone Miner Res"},{"issue":"157","key":"7612_CR141","doi-asserted-by":"publisher","first-page":"116342","DOI":"10.1016\/j.bone.2022.116342","volume":"1","author":"AM Rooney","year":"2022","unstructured":"Rooney AM, Dempster DW, Nieves JW, Zhou H, Bostrom MP, Cosman F (2022) Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck. Bone. 1(157):116342. https:\/\/doi.org\/10.1016\/j.bone.2022.116342","journal-title":"Bone."},{"key":"7612_CR142","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","volume":"37","author":"EF Eriksen","year":"2022","unstructured":"Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P (2022) Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res 37:36\u201340. https:\/\/doi.org\/10.1002\/jbmr.4457","journal-title":"J Bone Miner Res"},{"key":"7612_CR143","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2265.1992.tb02323.x","volume":"37","author":"JN Bradbeer","year":"1992","unstructured":"Bradbeer JN, Arlot ME, Meunler PJ, Reeve J (1992) Treatment of osteoporosis with parathyroid peptide (hPTH 1\u201334) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol (Oxf) 37:282\u2013289. https:\/\/doi.org\/10.1111\/j.1365-2265.1992.tb02323.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"7612_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bonekey.2014.56","volume":"3","author":"J-M Delaisse","year":"2014","unstructured":"Delaisse J-M (2014) The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. Bonekey Rep 3:1\u20138. https:\/\/doi.org\/10.1038\/bonekey.2014.56","journal-title":"Bonekey Rep"},{"key":"7612_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bonekey.2013.215","volume":"3","author":"NA Sims","year":"2014","unstructured":"Sims NA, Martin TJ (2014) Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep 3:1\u201310. https:\/\/doi.org\/10.1038\/bonekey.2013.215","journal-title":"Bonekey Rep"},{"key":"7612_CR146","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1002\/jbmr.3169","volume":"32","author":"DW Dempster","year":"2017","unstructured":"Dempster DW (2017) Tethering formation to resorption: reversal revisited. J Bone Miner Res 32:1389\u20131390. https:\/\/doi.org\/10.1002\/jbmr.3169","journal-title":"J Bone Miner Res"},{"key":"7612_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0152871","volume":"11","author":"RC Pereira","year":"2016","unstructured":"Pereira RC, Andersen TL, Friedman PA, Tumber N, Salusky IB, Wesseling-Perry K (2016) Bone canopies in pediatric renal osteodystrophy. PLoS ONE 11:1\u201314. https:\/\/doi.org\/10.1371\/journal.pone.0152871","journal-title":"PLoS ONE"},{"key":"7612_CR148","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/jbmr.3091","volume":"32","author":"NE Lassen","year":"2017","unstructured":"Lassen NE, Andersen TL, Pl\u00f8en GG, S\u00f8e K, Hauge EM, Harving S, Eschen GET, Delaisse JM (2017) Coupling of bone resorption and formation in real time: new knowledge gained from human Haversian BMUs. J Bone Miner Res 32:1395\u20131405. https:\/\/doi.org\/10.1002\/jbmr.3091","journal-title":"J Bone Miner Res"},{"key":"7612_CR149","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3949\/ccjm.88a.21011","volume":"88","author":"PD Miller","year":"2021","unstructured":"Miller PD, Lewiecki EM, Krohn K, Schwartz E (2021) Teriparatide: label changes and identifying patients for long-term use. Cleve Clin J Med 88:489\u2013493. https:\/\/doi.org\/10.3949\/ccjm.88a.21011","journal-title":"Cleve Clin J Med"},{"key":"7612_CR150","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/jbmr\/zjae057","volume":"39","author":"L Tripto-Shkolnik","year":"2024","unstructured":"Tripto-Shkolnik L, Szalat A, Tsvetov G, Rouach V, Sternberg C, Hoppe A, Burshtein G, Galitzer H, Toledano M, Harari G, Santora AC, Cosman F (2024) Oral daily PTH(1\u201334) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study. J Bone Miner Res 39:672\u2013682. https:\/\/doi.org\/10.1093\/jbmr\/zjae057","journal-title":"J Bone Miner Res"},{"key":"7612_CR151","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/jbmr.4274","volume":"36","author":"S Ish-Shalom","year":"2021","unstructured":"Ish-Shalom S, Caraco Y, Khazen NS, Gershinsky M, Szalat A, Schwartz P, Arbit E, Galitzer H, Tang JCY, Burshtein G, Rothner A, Raskin A, Blum M, Fraser WD (2021) Safety and efficacy of oral human parathyroid hormone (1\u201334) in hypoparathyroidism: an open-label study. J Bone Miner Res 36:1060\u20131068. https:\/\/doi.org\/10.1002\/jbmr.4274","journal-title":"J Bone Miner Res"},{"key":"7612_CR152","unstructured":"FDA, Drug trials snapshots Yorvipath, 2024. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-yorvipath."},{"key":"7612_CR153","unstructured":"EMA, Yorvipath, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/yorvipath."},{"key":"7612_CR154","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/jbmr.4726","volume":"38","author":"AA Khan","year":"2023","unstructured":"Khan AA, Rubin MR, Schwarz P, Vokes T, Shoback DM, Gagnon C, Palermo A, Marcocci C, Clarke BL, Abbott LG, Hofbauer LC, Kohlmeier L, Pihl S, An X, Eng WF, Smith AR, Ukena J, Sibley CT, Shu AD, Rejnmark L (2023) Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial. J Bone Miner Res 38:14\u201325. https:\/\/doi.org\/10.1002\/jbmr.4726","journal-title":"J Bone Miner Res"},{"key":"7612_CR155","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1056\/nejmc2302708","volume":"389","author":"RI Gafni","year":"2023","unstructured":"Gafni RI, Hartley IR, Roszko KL, Nemeth EF, Pozo KA, Lombardi E, Sridhar AV, Roberts MS, Fox JC, Collins MT (2023) Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1. N Engl J Med 389:1245\u20131247. https:\/\/doi.org\/10.1056\/nejmc2302708","journal-title":"N Engl J Med"},{"key":"7612_CR156","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/jbmr\/zjae196","volume":"40","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T, Nakamura Y (2025) Verifying the effectiveness of romosozumab re-administration on bone mineral density. J Bone Miner Res 40:201\u2013210. https:\/\/doi.org\/10.1093\/jbmr\/zjae196","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07612-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07612-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07612-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T13:31:07Z","timestamp":1764682267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07612-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":156,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7612"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07612-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}